Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim...
Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs